IMMUNOMEDICS, INC.: 10-Q filed 2016-11-02

Name: IMMUNOMEDICS, INC.: 10-Q filed 2016-11-02
Creator: IMMUNOMEDICS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What IMMUNOMEDICS, INC. reported in its quarterly report filed 2016-11-02 (fiscal Q1 2017): 26 published measures, 57 facts as tagged in accession 0001558370-16-009086.

This filing

Form: 10-Q (quarterly report)
Filed: 2016-11-02
Fiscal period: fiscal Q1 2017
Accession: 0001558370-16-009086 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All IMMUNOMEDICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit
At 2016-09-30	40,608,848	USD
At 2016-06-30	56,950,268	USD
At 2015-09-30	91,791,000	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2016-09-30	-72,235,630	USD
At 2016-06-30	-56,816,227	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2016-09-30	8,464,607	USD
At 2016-06-30	13,203,625	USD
At 2015-09-30	11,785,074	USD
At 2015-06-30	13,452,775	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-16,197,848	USD	92
2015-07-01 to 2015-09-30	-15,393,822	USD	92

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	647,572	USD	92
2015-07-01 to 2015-09-30	689,941	USD	92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2016-09-30	-384,702,802	USD
At 2016-06-30	-368,504,954	USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2015-07-01 to 2015-09-30	19,250	USD	92

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit
At 2016-09-30	4,477,597	USD
At 2016-06-30	3,969,163	USD
At 2015-09-30	2,764,000	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	774,042	USD	92
2015-07-01 to 2015-09-30	896,687	USD	92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-14,946,603	USD	92
2015-07-01 to 2015-09-30	-14,108,331	USD	92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2016-09-30	36,101,251	USD
At 2016-06-30	52,951,105	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	1,369,955	USD	92
2015-07-01 to 2015-09-30	1,369,955	USD	92

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2016-09-30	14,325,254	USD
At 2016-06-30	15,423,561	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2016-09-30	584,410	USD
At 2016-06-30	513,992	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2016-09-30	329,391	USD
At 2016-06-30	350,524	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	14,525,864	USD	92
2015-07-01 to 2015-09-30	12,913,130	USD	92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2016-09-30	95,942,855	shares
At 2016-06-30	95,832,573	shares

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit
At 2016-09-30	-127,727	USD
At 2016-06-30	-132,226	USD
At 2015-09-30	-110,000	USD
At 2015-06-30	-161,000	USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

Period	Value	Unit	Days
At 2016-09-30	-72,977,415	USD
At 2016-06-30	-57,526,967	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2016-09-30	28,870,579	USD
At 2016-06-30	28,637,606	USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2016-09-30	30,000	USD
At 2016-06-30	30,000	USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

Period	Value	Unit	Days
At 2016-09-30	1,724,155	USD
At 2016-06-30	1,699,276	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-16,228,893	USD	92
2015-07-01 to 2015-09-30	-15,396,789	USD	92

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-16,228,893	USD	92
2015-07-01 to 2015-09-30	-15,416,039	USD	92

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	-16,193,349	USD	92
2015-07-01 to 2015-09-30	-15,342,657	USD	92

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	691,584	USD	92
2015-07-01 to 2015-09-30	1,724,294	USD	92

Inspect the source

Entity: IMMUNOMEDICS, INC. / CIK 0000722830
Captured: 2026-09-22 19:30 UTC
SEC response SHA-256: d9e652f20067bb0e424f518a6160c3705c40f702f691a59fdf4f1d40e5e05b37

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000722830.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))